Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07581041 · ClinicalTrials.gov registry record · NA
Studying the Impacts of Higher Taxes and Bans on Electronic Cigarettes to Improve Public Health
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 3,400
- Enrollment target
NCT07581041: Clinical Trial NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT07581041 is a NA study that has not yet begun recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 3,400 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (142% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07581041, a NA study, has not yet begun recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 3,400 participants
- Enrollment target
Study Summary
This clinical trial studies whether imposing higher taxes and bans on electronic cigarettes (EC) with appealing features impacts tobacco use among current and susceptible adolescents and young adults (AYA) EC users and adults who use EC or are open to EC use. ECs are currently the most popular form of nicotine or tobacco product in the United States. Compared to burned cigarette products, ECs generally pose fewer short-term harms, making them a promising tool for lowering users' exposure to toxins and cancer-causing chemicals from smoking, promoting better public health outcomes. However, evidence shows that EC marketing has increased overall initiation into nicotine use among AYAs, and that EC users are at a higher risk of becoming smokers, which could have negative public health outcomes. Therefore, understanding the public health impact of EC use and regulation remains a major goal in tobacco control research. This trial studies different scenarios which impose higher taxes or bans on ECs with appealing features. Researchers hope that by studying participant responses to the different scenarios they may be able to identify which ones best discourage EC use among AYAs while promoting adult EC users to quit smoking, which may improve public health.
Primary Outcome
Will examine how tiered taxes on AYA-appealing features (flavors, product type, nicotine concentration) impact EC use among current and susceptible AYA EC users. All hypotheses will be tested using regression analyses. Will use count data models, such as the Negative Binomial model, the Poisson model, and Multiple Discrete-Continuous Extreme Value (MDCEV) Model. Will use clustered sandwich estimators and consider mixed effects, random effects, and fixed effects in the modeling to account for the
Interventions
- OTHER Survey Administration
- OTHER Discrete Choice Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,400 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What is known before NCT07581041 opens enrollment
NCT07581041 is an interventional study that assigns participants to a tested intervention. Its 3,400 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (142% higher).
The record links to 0 conditions, and to 2 interventions - of which Survey Administration is the first listed.
NCT07581041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07581041 about?
NCT07581041 is a clinical study titled "Studying the Impacts of Higher Taxes and Bans on Electronic Cigarettes to Improve Public Health". This clinical trial studies whether imposing higher taxes and bans on electronic cigarettes (EC) with appealing features impacts tobacco use among current and susceptible adolescents and young adults (AYA) EC users and adults who use EC or are open to EC use. ECs are currently the most popular form ...
What is the current status of trial NCT07581041?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 3,400 participants. The study started on 2026-08-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07581041?
The interventions under investigation include: Survey Administration (OTHER), Discrete Choice Study (OTHER).
Who is sponsoring clinical trial NCT07581041?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07581041's enrollment target sits among peer trials
3,400 37th of 2000 higher than 1,964 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI